Lung cancer rewires its metabolism into a dynamic, adaptive network

Lung cancer kills more people worldwide than any other malignancy, and decades of research have mapped its genetic and epigenetic drivers in remarkable detail. Yet a growing body of evidence now points to a parallel layer of control that has long been underestimated: metabolism. A new review published in Cellular and Molecular Life Sciences by Sara Gholamhosseinian-Najjar and Christian Frezza of the University of Cologne argues that lung tumours should no longer be viewed as cells running a handful of isolated biochemical pathways, but as integrated, highly adaptable metabolic networks whose organisation depends on lineage identity, oncogenic state and the pressures of the tumour microenvironment.

The central claim of the review is that lung cancer cells do not rely on a single nutrient source. Instead, they weave together glucose and glutamine utilisation, fatty acid oxidation and synthesis, one-carbon and nucleotide metabolism, and redox-supporting circuits into a context-dependent program. This integration allows tumour cells to keep growing when nutrients become scarce, to maintain redox homeostasis under oxidative stress, and to survive the metabolic insults delivered by chemotherapy, radiotherapy and targeted agents. Metabolic flexibility, in other words, is not a side effect of transformation but a functional pillar of malignancy.

Technically, the picture that emerges is one of subtype-specific metabolic states constrained by histology and genetics. Non-small cell lung cancer, which includes adenocarcinoma, squamous cell carcinoma and large cell variants, displays metabolic programs shaped by distinct oncogenic drivers such as mutations in KRAS, EGFR and ALK rearrangements, each imposing different demands on carbon and nitrogen flux. Small cell lung cancer, driven largely by loss of TP53 and RB1 and characterised by neuroendocrine lineage features, operates under different biosynthetic constraints. What unites these entities is not a shared metabolic signature but a shared capacity: the ability to shift rapidly between alternative nutrients and biosynthetic routes when the preferred ones are limited.

Glucose metabolism remains the most intensively studied arm of this network. The Warburg effect, the tendency of cancer cells to ferment glucose to lactate even in the presence of oxygen, supplies biosynthetic intermediates and supports rapid proliferation, but the review emphasises that glycolysis is dynamically regulated rather than fixed. Lung cancer cells can dial glycolytic flux up or down depending on oxygen availability, nutrient supply and therapeutic pressure, and they reroute glucose-derived carbon into the pentose phosphate pathway to generate NADPH for antioxidant defence and into serine and one-carbon metabolism to feed nucleotide synthesis and methyl-group supply.

Glutamine serves as the complementary hub, providing nitrogen for nucleotide and amino acid biosynthesis and carbon that enters the tricarboxylic acid cycle through glutaminolysis. The interplay between glucose and glutamine is particularly instructive: when one carbon source is constrained, lung cancer cells frequently compensate by increasing dependence on the other, a phenomenon that explains why single-pathway inhibitors have repeatedly disappointed in the clinic. The same logic extends to fatty acid metabolism, where tumour cells toggle between de novo lipogenesis to build membranes and fatty acid oxidation to generate ATP and reducing equivalents during energy stress.

One-carbon metabolism and nucleotide biosynthesis emerge as critical supporting circuits. Folate-mediated one-carbon reactions fuel purine and thymidylate synthesis while also feeding the transsulphuration pathway and glutathione production, linking proliferation to redox control. The review also highlights sulphur metabolism as an underappreciated contributor, with cysteine and methionine handling supporting antioxidant capacity and epigenetic regulation through methylation reactions. These circuits do not operate in isolation; they are cross-wired so that a block in one route can be bypassed by another, maintaining the overall network output.

This adaptability has direct therapeutic consequences. The review identifies subtype-specific metabolic dependencies that could be exploited clinically, but it also explains why resistance develops so readily: when a tumour is pushed off one metabolic route, it shifts to another, maintaining growth and redox balance. Combination strategies that anticipate these compensatory shifts, rather than targeting single enzymes, are therefore proposed as the more promising path forward. Metabolomics, the systematic measurement of small-molecule intermediates, is positioned as a key technology for identifying these dependencies and for monitoring how metabolic states change during treatment.

The authors frame their synthesis as a conceptual correction. Metabolic reprogramming has only recently been recognised as a major determinant of tumour progression and therapeutic response in lung cancer, and the field has tended to catalogue pathways rather than model them as a system. By presenting lung cancer metabolism as an integrated and adaptable network, the review offers a framework for thinking about how oncogenic mutations, lineage programs and environmental conditions jointly shape metabolic organisation, and how that organisation can be perturbed therapeutically.

For readers following cancer metabolism, the takeaway is that flexibility itself may be the most important target. Rather than asking which single nutrient a lung tumour depends on, researchers and clinicians may need to ask which shifts it can make, how fast it can make them, and which combinations of vulnerabilities emerge when its escape routes are mapped in advance. As lung cancer continues to lead global cancer mortality, understanding the tumour as a dynamic metabolic network rather than a collection of pathways may prove essential for converting metabolic knowledge into durable therapeutic benefit.

Subject of Research: Cancer Metabolism

Article Title: Lung cancer metabolism: a dynamic and adaptive network

Article References: Gholamhosseinian-Najjar, S., & Frezza, C. (2026). Lung cancer metabolism: a dynamic and adaptive network. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06417-5

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06417-5

Keywords: lung cancer, cancer metabolism, metabolic plasticity, glucose metabolism, glutamine metabolism, nucleotide metabolism, redox homeostasis, Cellular and Molecular Life Sciences, Lung, cancer, metabolism, dynamic